Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2026)

Mirum Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $310.3 million for Q1 2026.

• On a quarterly basis, Convertible Debt rose 0.56% year-over-year to $310.3 million in Q1 2026; TTM through Mar 2026 was $310.3 million, a 0.56% increase from a year earlier, with the FY2025 full-year figure at $309.8 million, up 0.56% from the prior year.
• Convertible Debt steadied at $310.3 million in Q1 2026 per MIRM's latest filing, from $309.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $310.3 million in Q1 2026 and bottomed at $305.6 million in Q2 2023.
• The 4-year median for Convertible Debt is $307.9 million (2024), against an average of $307.9 million.
• Across the five-year window, Convertible Debt climbed 0.53% in 2024 and rose 0.56% in 2026, its largest moves.
• Year by year, Convertible Debt stood at $306.4 million in 2023, then gained by 0.54% to $308.1 million in 2024, then climbed by 0.56% to $309.8 million in 2025, then grew by 0.15% to $310.3 million in 2026.
• Per Business Quant, the three latest MIRM Convertible Debt figures stand at $310.3 million (Q1 2026), $309.8 million (Q4 2025), and $309.4 million (Q3 2025).